Palonosetron: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
HAS (France) and SMC (Scotland) recommended or restricted palonosetron, while AWMSG (Wales) and TLV (Sweden) did not recommend it.
On the same population the two systems disagree outright: SMC (Scotland) recorded recommended for “Prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and prevention of nausea and vomiting associated with moderately emetogenic …”, while AWMSG (Wales) recorded not recommended for “For the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and prevention of …”.
Assessment has run over 9.5 years, from 3 Jan 2007 at HAS (France) to 20 Jul 2016 at HAS (France).
No assessment is on file from PBAC (Australia), PHARMAC (New Zealand), CIPM (Spain) and G-BA (Germany), each among the eight highest-volume agencies here.
Nothing has been added since 2016; on this evidence the file is dormant.
HAS (France) was first to assess palonosetron, on 3 Jan 2007; AWMSG (Wales) did not open a file until 30 Jun 2015 — an unusually long tail of 8.4 years between the earliest and latest system to look at it.
The record arrives in waves: 3 separate years each carry two or more decisions, spread across 5 years in total.
2 of the 4 agencies here assessed palonosetron more than once, HAS (France) most often at 4 entries — repeat review is the norm for this molecule rather than the exception.
Coverage is narrow: only 4 of the 18 agencies here have assessed palonosetron.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| HAS (France) | 20 Jul 2016 | Listing (Transparency Committee) | SMR substantial · ASMR V | source |
| HAS (France) | 3 Feb 2016 | Indication extension | SMR substantial · ASMR V | source |
| SMC (Scotland) | 10 Aug 2015 | Prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and prevention of nausea and vomiting associated with moderately emetogenic … | accepted | source |
| AWMSG (Wales) | 30 Jun 2015 | For the prevention of acute nausea and vomiting associated with highly emetogenic cancer chemotherapy and prevention of … | not endorsed (non-submission) | source |
| TLV (Sweden) | 12 Dec 2013 | Vi beslutar att Aloxi inte ska ingå i högkostnadsskyddet | rejection or exclusion | source |
3 further decisions for palonosetron, across 2 agencies, are not shown here. They link to 1 further source document.
Related molecules
- aprepitant — same ATC class A04A — Antiemetics
- ondansetron — same ATC class A04A — Antiemetics
- netupitant / palonosetron — same ATC class A04A — Antiemetics
- granisetron — same ATC class A04A — Antiemetics
- fosaprepitant — same ATC class A04A — Antiemetics
- bevacizumab — also decided by HAS in 2016Q3
Coverage: 8 decisions for palonosetron from 4 agencies, 2007 to 2016. Data to 7 Sep 2026. ATC class A04A — Antiemetics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.